Priced at a premium to peer multiples and intrinsic cash flows, demanding strong execution to justify current levels.
Fragile underlying quality score of 30/100; weak margins or elevated debt leverage warrant caution.
Wall Street forecasts a balanced outlook with consensus price targets near the current price.
Verdict: Highly distressed profile flashing severe fundamental warning signs.
Wall Street sentiment is generally neutral. However, capital return yields remain modest, driven predominantly by aggressive share repurchases.
MHLA struggles with subpar profitability and pressured margins. This is backed by a fortress balance sheet, holding significant net cash ($35M) and minimal debt risk.
The company is facing top-line contraction (-17.0% 3Y CAGR) paired with stable bottom-line earnings. Operating efficiency remains adequate with margins around 8.5%.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $14.0M | -36.8% | -17.0% | -37.2% | -31.2% | |
| EBITDA | -$3.8M | — | -31.7% | — | — | |
| Net Income | -$8.6M | -421.1% | — | — | — | |
| EPS (Diluted) | $-0.09 | -428.9% | — | — | — | |
| Free Cash Flow | -$21.1M | -12.8% | +44.5% | +43.2% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | 8.5% | 49.9% | 58.4% | 26.1% |
| Net Margin | -507.6% | -167.5% | -90.6% | -49.6% |
| FCF Margin | -232.4% | -174.5% | -243.6% | -133.9% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q3'23Latest | — | $-0.04 | — | ||
| Q1'23 | — | $-0.11 | — | ||
| Q4'22 | — | $0.25 | — |
Total return is -17.8% (1Y), lagging the benchmark by -38.6%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -12.1% | -19.4% | — |
| 1Y | -17.8% | -38.6% | +11.1% |
| 3YCAGR | -1.9% | -22.4% | +30.1% |
| 5YCAGR | -2.9% | -14.6% | +37.8% |
| 10YCAGR | +0.8% | -12.9% | — |
The S&P 500 is at 30.6x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Maiden Holdings, Ltd. 6.625 NT 2046 (MHLA) valuation, health, and returns.
Maiden Holdings, Ltd. 6.625 NT 2046 is estimated to be overvalued under our discounted cash flow framework. relative multiples indicate the stock is Limited: Expensive versus peers compared to industry peers. overvalued (implying -96.1% downside from DCF intrinsic value of $0.41)
Maiden Holdings, Ltd. 6.625 NT 2046 has multiple valuation anchors: DCF Intrinsic Value: $0.41 | Peer Relative Fair Value: $0.60. A convergence of these signals offers higher conviction.
Maiden Holdings, Ltd. 6.625 NT 2046 displays weak financial health with a composite quality score of 30/100, supported by a Piotroski F-Score of 2/9, Return on Invested Capital (ROIC) of 4.3%.
Maiden Holdings, Ltd. 6.625 NT 2046 does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Maiden Holdings, Ltd. 6.625 NT 2046's current growth trajectory is Decelerating. The company achieved -36.8% 1Y revenue growth and -428.9% 1Y EPS growth, compared to its 3Y revenue CAGR of -17.0%.
Wall Street consensus is Hold based on 0 analysts. The consensus price target represents a N/A change from current levels.
Investment risks for Maiden Holdings, Ltd. 6.625 NT 2046 include: -34.8% 1-year max drawdown. Volatility risk is characterized by a beta of -0.02x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.